Page last updated: 2024-09-05

lapatinib and carboplatin

lapatinib has been researched along with carboplatin in 14 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(carboplatin)
Trials
(carboplatin)
Recent Studies (post-2010) (carboplatin)
1,9193051,44212,8954,0015,244

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (21.43)29.6817
2010's10 (71.43)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Alvarez, RD; Barnes, MN; Estes, JM; Kimball, KJ; Kirby, TO; Koch, KM; Matei, DE; Numnum, TM; Zamboni, WC1
Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S1
Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y1
Crane, K1
Bell, R; Khasraw, M1
Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W1
Candon, D; Crown, J; Healy, J1
Piccart, M; Sonnenblick, A1
Blohmer, JU; Darb-Esfahani, S; Denkert, C; Dietel, M; Endris, V; Jackisch, C; Klare, P; Kümmel, S; Loi, S; Loibl, S; Möbs, M; Nekljudova, V; Reimer, T; Salat, C; Schem, C; Schmitt, W; Sinn, B; Sinn, P; Stenzinger, A; Tesch, H; Untch, M; von Minckwitz, G; Weichert, W1
Breathnach, O; Carr, A; Crown, J; Duke, D; Eustace, AJ; Fay, J; Gallagher, W; Grogan, L; Gullo, G; Hambly, N; Hennessy, BT; Hill, AD; Kay, EW; Kelly, C; Kennedy, MJ; Madden, SF; Milewska, M; Moulton, B; O'Donovan, N; Power, C; Sheehan, KM; Teiserskiene, A; Toomey, S; Walshe, J1
Li, B; Li, Y; Liu, Z; Shu, T; Wu, X1
Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U; Williams, F1
Bueno, C; Carolla, RL; Chen, B; Hillman, DW; Jenkins, RB; Johnson, DB; Leon-Ferre, RA; Moreno-Aspitia, A; Northfelt, DW; Perez, AT; Perez, EA; Zon, RT1

Reviews

2 review(s) available for lapatinib and carboplatin

ArticleYear
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab

2012
Adjuvant systemic therapy in breast cancer: quo vadis?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms

2015

Trials

3 trial(s) available for lapatinib and carboplatin

ArticleYear
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Gynecologic oncology, 2008, Volume: 111, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines

2008
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Breast cancer research : BCR, 2017, Jul-27, Volume: 19, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Taxoids; Trastuzumab

2017
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
    Breast cancer research and treatment, 2020, Volume: 182, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab

2020

Other Studies

9 other study(ies) available for lapatinib and carboplatin

ArticleYear
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
    Clinical breast cancer, 2005, Volume: 6, Issue:5

    Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab

2005
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
    Dermatology online journal, 2009, Mar-15, Volume: 15, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine

2009
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays

2010
Elucidating an uncommon disease: inflammatory breast cancer.
    Journal of the National Cancer Institute, 2011, Sep-21, Volume: 103, Issue:18

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome

2011
Predicting drug responsiveness in human cancers using genetically engineered mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-01, Volume: 19, Issue:17

    Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment

2013
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
    Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab

2014
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Oncotarget, 2016, 10-18, Volume: 7, Issue:42

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53

2016
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Cancer letters, 2017, 12-28, Volume: 411

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cystadenocarcinoma, Serous; Down-Regulation; Female; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Middle Aged; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Ubiquitin-Protein Ligases

2017
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
    Scientific reports, 2019, 11-26, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Paclitaxel; Peritoneal Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays

2019